Background and Objective:Expression of Skp2 was related with the prognosis of several tumors.However,there was no intensive study on the relationship between Skp2 and extranodal NK/T-cell lymphoma.This study was to explore the role of Skp2 in extranodal NK/T-cell lymphoma.Methods:The clinicopathological data of 39 patients with extranodal NK/T-cell lymphoma were analyzed.The expression of Skp2 was examined by immunohistochemistry on formalin-fixed,paraffin-embedded tissue sections.Results:Among the patients with high expression of Skp2,complete remission(CR) rate was only 14.3%(2/14).However,CR rate among the patients with low expression of Skp2 was 68.0%(17/25).Significant difference was shown between these two groups(P < 0.001).In the group of low expression,the median overall survival(OS) was 85.59 months(95% CI:35.83-135.34 months),the 1-and 2-year OS rates were 81% and 71%,respectively.However,in the group of high expression,the median OS was only 9.73 months(95% CI:2.05-17.40 months),the 1-and 2-year OS rates were 42% and 14%,respectively.There was statistical difference between these two groups(P < 0.001).Multivariate analysis showed that Skp2 expression(P <0.001),LDH(P = 0.026) and ECOG PS(P = 0.003) were dependent prognostic factors of extranodal NK/T-cell lymphoma.Conclusion:High expression of Skp2 is an independent unfavorite adverse prognostic factor of extranodal NK/T-cell lymphoma.
哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)是PI3K/Akt通路的下游分子,可接受生长因子、营养、能量等多种信号,是细胞生长和增殖的关键调节分子。许多肿瘤中存在有编码mTOR信号通路相关蛋白的基因突变,这些蛋白的异常表达可引起mTOR通路的过度激活。目前,以mTOR为治疗靶点成为肿瘤治疗的研究新热点。本文就近年来有关mTOR通路及其抑制剂在抗肿瘤方面的研究进展作一综述。
